July 9, 2025 4:34pm
Navigating by adapting to sentiment resilience
Remember, not to be a spoil-sport, the tide will go out when “uncle algo and his electronic dwarfs” surf in
I say what others won’t, so you can do what others can’t!
I also try to answer as many whys, as I can … while providing the metrics to validate my thesis
Never leave an investor uninformed!
My perspective is retail investors should continue to roll-the-dice until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!
RegMed Investors’ (RMi) pre-open: The sector is what it is, until it isn’t and even then, it doesn’t seem to be … https://www.regmedinvestors.com/articles/13989
Tuesday night’s RegMed Investors (RMi) Closing Bell: Recovery … https://www.regmedinvestors.com/articles/13988
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812
Wednesday: The Dow closed UP +217.54 points or +0.49%, the S&P closed UP +37.74 points or +0.61% while the Nasdaq closed UP +192.87 points or +0.95%
- Theme of the session, traders seemingly downplayed the latest tariff-related headlines of the week
Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy
- An econ update re Fed rate cuts, “Job gains have slowed considerably, though the rate of nonfarm payrolls growth has consistent surprised economists. June showed an increase of 147,000, against the consensus forecast for 110,000, while the unemployment rate unexpectedly fell to 4.1%. Consumer spending has slowed considerably. Personal expenditures declined 0.1% in May, while retail sales tumbled 0.9%.”
Wednesday’s advance/decline line opened positive with 27 incliners, 5 decliners and 3 flats ending with a positive close of 28 incliners, 5 decliners and 2 flats
Metrics: Wednesday, the IBB was up +2.98%, the XBI was up +3.16% while the VIX was down -0.90 points or -5.36% at 15.01
Q3 – 7/25 – 1 market holiday, 5 positive and 1 negative closes
Q2/25:
- June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
- May – 1 market holiday, 10 negative and 11 positive closes
- April – 11 positive and 10 negative closes
Wednesday Closing UP (10 of 28) +$ after Tuesday’s
- CRISPR Therapeutics (CRSP +$5.28 after Tuesday’s +$3.62 after Monday’s -$0.980,
- Lenz Therapeutics (LENZ +$3.46 after Tuesday’s -$0.12 after Monday’s -$1.11),
- Alnylam Pharmaceuticals (ALNY +$3.32 after Tuesday’s -$6.63 after Monday’s -$7.78),
- Ultragenyx Pharmaceuticals (RARE +$2.00 after Tuesday’s -$0.19),
- Ionis Pharmaceuticals (IONS +$1.48 after Tuesday’s -$0.46 after Monday’s -$1.22)
- Vericel (VCEL +$1.26 after Tuesday’s +$0.76 after Monday’s -$2.33),
- Beam Therapeutics (BEAM +$1.17 after Tuesday’s +$1.11 after Monday’s -$0.83),
- Intellia Therapeutics (NTLA +$1.02 after Tuesday’s+$0.87 after Monday’s -$0.49),
- uniQure NV (QURE +$0.45),
- Prime Medicine (PRME +$0.445),
Flat (2)
- bluebird bio (BLUE) P/E acquired
- Homology Medicine (FIXX)
Wednesday’s Closing DOWN (5 of 5):
- BioLife Solutions (BLFS -$0.23 after Tuesday’s +$0.74 after Monday’s -$1.03),
- Harvard Apparatus RT (OTCQB: HRGN -$0.15 after Tuesday’s -$0.14 after Monday’s $0.00),
- Brainstorm Cell Therapeutics (BCLI -$0.07),
- MiMedx (MDXG -$0.05 after Tuesday’s +$0.52 after Monday’s +$0.15),
- Verve Therapeutics (VERV -$0.02 after Tuesday’s -$0.03),
The BOTTOM LINE: Indexes rose on Wednesday as the cell and gene therapy sector piled-on further upside…
Cell and gene therapy sector equities on Wednesday continued the upside after Tuesday positive close after diving on Monday ….
- After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.
Fed minutes released showed only "a couple" of Fed officials at the June meeting supported interest rate cuts as soon as this month.
- The minutes released on Wednesday afternoon give investors a glimpse at what Fed officials may do when they meet later this month.
- The market currently forecasts that a rate cut would not come earlier than September, despite President Trump's vocal calls for Fed Chair Powell to cut rates.
- At the June meeting, policymakers held interest rates steady, leading traders to bet that 2 rate cuts this year are likely.
As I also wrote, the “June Swoon” is over … however, July will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”
- There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.
Last session of June as July evolves ‘25: understand the “flow” …
- 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
- 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
- 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats
- 7/4 – Friday market holiday
- 7/3 – Thursday closed positive with 23 positive, 6 negative and 6 flats
- 7/2 - Wednesday closed positive with 24 positive, 7 negative and 4 flats
- 7/1 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
- If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
- I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!
Why do I keep repeating, so investors can make the connection …
The top three (3) performing in the session:
- Wednesday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)
- Tuesday: CRISPR Therapeutics (CRSP), Moderna (MRNA) and Beam Therapeutics (BEAM)
- Monday: Prime Medicine (PRME), AxoGen (AXGN) and MiMedx (MDXG)
The worst three (3) in the session:
- Wednesday: BioLife Solutions (BLFS), Harvard apparatus RT (OTCQB: HRGN) and Brainstorm Cell Therapeutics (BCLI)
- Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Agenus (AGEN)
- Monday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Lenz Therapeutics (LENZ)
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
